Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC
I'm PortAI, I can summarize articles.
Nuvectis Pharma Inc. has initiated a Phase 1b clinical trial to evaluate the combination of NXP900 and osimertinib in EGFR-mutated NSCLC patients resistant to osimertinib. The trial aims to assess the safety and clinical activity of this combination. Data readouts are expected in 2026, with updates anticipated throughout the year. The news was published by Nuvectis Pharma via GlobeNewswire on December 17, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments